Predictive role of SLC1A5 in neuroblastoma prognosis and immunotherapy
Abstract Background Neuroblastoma, a prevalent extracranial solid tumor in pediatric patients, demonstrates significant clinical heterogeneity, ranging from spontaneous regression to aggressive metastatic disease. Despite advances in treatment, high-risk neuroblastoma remains associated with poor su...
Saved in:
| Main Authors: | Jian Cheng, Miaomiao Sun, Xiao Dong, Yang Yang, Xiaohan Qin, Xing Zhou, Yongcheng Fu, Yuanyuan Wang, Jingyue Wang, Da Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13560-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11
by: Vid Mlakar, et al.
Published: (2024-12-01) -
Trained autologous cytotoxic T-cells derived from PBMCs or splenocytes for immunotherapy of neuroblastoma
by: Xiaofang Wu, et al.
Published: (2025-06-01) -
Exosomes and immune modulation: implications for neuroblastoma immunotherapy
by: Martina Morini, et al.
Published: (2025-05-01) -
Identification of novel biomarkers and prognostic model for neuroblastoma using Mendelian randomization and transcriptomic analysis
by: Yongcheng Fu, et al.
Published: (2025-04-01) -
Machine learning-driven SLC prognostic signature for glioma: predicting survival and immunotherapy response
by: Jianghua Lin, et al.
Published: (2025-06-01)